Skip to main content
. 2022 Aug 3;14:17588359221116604. doi: 10.1177/17588359221116604

Figure 4.

Figure 4.

One-way sensitivity analysis in patients with non-epithelioid histology (N).

C, pemetrexed plus cisplatin/carboplatin; ICER, incremental cost-effectiveness ratio; NI, nivolumab plus ipilimumab; P, probability; PD, progressive disease; PFS, progression-free survival.